News

Avelumab shows modest, durable responses in advanced penile cancer, highlighting the need for innovative treatments in this challenging patient population.

Discover the latest advancements in oncology, including FDA approvals, groundbreaking trial results, and expert insights shaping cancer treatment today.

A phase 2 trial reveals single-dose carboplatin plus radiotherapy offers exceptional long-term survival and minimal toxicity for stage IIa/b seminoma patients.

The FDA clears the EXENT System, enhancing multiple myeloma diagnosis with automated workflows and improved sensitivity for clinical laboratories.

The FDA accepts 177Lu-edotreotide for GEP-NETs, showcasing significant survival benefits over everolimus in recent trials.

New research reveals that radiotherapy benefits prostate cancer patients with fewer metastases, refining treatment strategies for advanced cases.

A groundbreaking study reveals that less frequent dosing of pasritamig enhances immune response in advanced prostate cancer, challenging traditional treatment assumptions.

The FDA grants fast track designation to 4A10, a promising monoclonal antibody for treating relapsed acute lymphoblastic leukemia in children.

FOG-001 receives FDA fast track designation, promising new hope for desmoid tumor patients with its innovative approach to treatment.

New data reveals detalimogene's promising efficacy and safety in treating high-risk bladder cancer, offering hope for improved patient outcomes.

MB-105 receives FDA RMAT designation, advancing treatment options for relapsed T-cell lymphoma and highlighting its promising clinical potential.

The FDA approves ziftomenib for relapsed mNPM1 AML, offering new hope with promising efficacy and safety data for patients.

New clinical trial data highlight the promising antitumor effects of imneskibart combined with aldesleukin in patients with melanoma and NSCLC.

Experts discuss the need for global collaboration to enhance cancer care in rural areas, addressing access, workforce challenges, and diverse patient needs.

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies.

The FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell lymphomas.

Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.

A groundbreaking clinical trial begins for 225Ac-SSO110, targeting aggressive cancers like extensive-stage small cell lung cancer and Merkel cell carcinoma.

During a live event, Anthony B. El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

The FDA fast-tracks AVZO-1418, a promising treatment for EGFR-mutated lung cancer, enhancing development and approval processes for patients in need.

The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and acute lymphoblastic leukemia.

New trial data reveals STK-012 combined with pembrolizumab and chemotherapy shows promising efficacy in treating PD-L1 negative non-small cell lung cancer.

A new treatment combination shows significant promise for patients with resistant gastrointestinal stromal tumors, improving survival rates and tolerability.

A coclinical trial reveals a promising triplet therapy for advanced HR+ breast cancer, highlighting the importance of genetic profiling in treatment efficacy.